Savara Inc (SVRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Savara Inc (SVRA) has a cash flow conversion efficiency ratio of -0.207x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.75 Million) by net assets ($143.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Savara Inc worth for the company's overall valuation and market capitalisation.
Savara Inc - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Savara Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Savara Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Savara Inc ranked by their cash flow conversion efficiency. Explore SVRA cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuhan Fingu Electronic Technology Co Ltd
SHE:002194
|
0.036x |
|
ARB Corporation Ltd
AU:ARB
|
0.087x |
|
Arendals Fossekompani ASA
OL:AFK
|
0.013x |
|
Virtus Investment Partners, Inc.
NASDAQ:VRTS
|
0.106x |
|
Lelon Electronics Corp
TW:2472
|
0.021x |
|
Loma Negra Compañía Industrial Argentina Sociedad Anónima
F:8LN
|
0.016x |
|
Jiangyin Hengrun Heavy
SHG:603985
|
0.009x |
|
Talant Optronics (Suzhou) Co. Ltd.
SHE:301045
|
N/A |
Annual Cash Flow Conversion Efficiency for Savara Inc (2000–2025)
The table below shows the annual cash flow conversion efficiency of Savara Inc from 2000 to 2025. View current stock price of Savara Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $203.13 Million | $-101.04 Million | -0.497x | +4.28% |
| 2024-12-31 | $171.45 Million | $-89.09 Million | -0.520x | -42.85% |
| 2023-12-31 | $140.37 Million | $-51.06 Million | -0.364x | -13.46% |
| 2022-12-31 | $107.78 Million | $-34.55 Million | -0.321x | -15.58% |
| 2021-12-31 | $144.50 Million | $-40.08 Million | -0.277x | +55.17% |
| 2020-12-31 | $64.38 Million | $-39.84 Million | -0.619x | -39.45% |
| 2019-12-31 | $101.70 Million | $-45.12 Million | -0.444x | -- |
| 2018-12-31 | $0.00 | $-39.27 Million | x | -- |
| 2017-12-31 | $119.31 Million | $-28.23 Million | -0.237x | -201.43% |
| 2016-12-31 | $-35.88 Million | $-8.37 Million | 0.233x | +116.92% |
| 2015-12-31 | $23.89 Million | $-32.95 Million | -1.379x | -228.28% |
| 2014-12-31 | $58.66 Million | $-24.64 Million | -0.420x | -12.91% |
| 2013-12-31 | $47.81 Million | $-17.79 Million | -0.372x | -11.72% |
| 2012-12-31 | $41.79 Million | $-13.92 Million | -0.333x | -40.42% |
| 2011-12-31 | $56.78 Million | $-13.47 Million | -0.237x | +24.12% |
| 2010-12-31 | $26.69 Million | $-8.34 Million | -0.313x | +83.47% |
| 2009-12-31 | $6.67 Million | $-12.62 Million | -1.891x | +52.35% |
| 2008-12-31 | $6.00 Million | $-23.79 Million | -3.968x | -526.87% |
| 2007-12-31 | $31.03 Million | $-19.64 Million | -0.633x | +19.92% |
| 2006-12-31 | $19.96 Million | $-15.77 Million | -0.790x | -153.12% |
| 2005-12-31 | $-7.83 Million | $-11.65 Million | 1.488x | +456.18% |
| 2004-12-31 | $12.39 Million | $-5.18 Million | -0.418x | +23.41% |
| 2003-12-31 | $4.12 Million | $-2.25 Million | -0.545x | -142.20% |
| 2002-12-31 | $-852.73K | $-1.10 Million | 1.292x | -51.78% |
| 2001-12-31 | $-638.49K | $-1.71 Million | 2.680x | +1922.59% |
| 2000-12-31 | $14.61 Million | $-2.15 Million | -0.147x | -- |
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, P… Read more